DFDominik Faust

Dominik Faust

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dominik Faust has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Jürgen Stein

    DGD Kliniken Frankfurt Sachsenhausen

    3 shared publications
  • V. Milovic

    2nd Department of Medicine, Johann Wolfgang Goethe University, Theodor-Stern-Kai, 60590 Frankfurt, Germany

    3 shared publications
  • Bora Akoglu

    2nd Department of Medicine Gastroenterology, Johann Wolfgang Goethe-University, Theodor Stern Kai 7, 60590 Frankfurt, Germany

    2 shared publications
  • S. Hormann

    2nd Department of Medicine, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany

    2 shared publications
  • Vladan Milovic

    2nd Department of Medicine Gastroenterology, Johann Wolfgang Goethe-University, Frankfurt, Germany

    2 shared publications
  • A.C. Faust

    2nd Department of Medicine, Johann Wolfgang Goethe University, Theodor-Stern-Kai, 60590 Frankfurt, Germany

    1 shared publication

Latest Publications

  • Hyperproliferation of homocysteinetreated colon cancer cells is reversed by folate and 5-methyltetrahydrofolate

    by Bora Akoglu, Vladan Milovic, Wolfgang F. Caspary, Dominik Faust

    Summary. Background: There is an increasing evidence, stemming from epidemiological studies as well as studies performed in human biopsies and animal and cell culture models, suggesting that folate is chemopreventive in colonic carcinogenesis. Hyperhomocysteinemia is frequently associated with folate deficiency. Homocysteine, an amino acid, is metabolized to methionine in a 5-methyltetrahydrofolate (5-MTHF) dependent reaction. Aim of the study: The aim of this study was i) to evaluate the effects of folate and its metabolites on growth and cell cycle progression in human colon cancer cells (Caco-2) in culture, and ii) to assess the effects of exogenous homocysteine on colon cancer cell proliferation. iii) Having found that homocysteine enhances colon cancer cell growth while metabolites of folate inhibit cell proliferation, we investigated the effects of simultaneous treatment in colon cancer cells. Methods: Caco-2 cells were incubated either with homocysteine (0.1–10 µM), and/or with folic acid and its metabolites (0.625–10 µg/ml). Cell proliferation was determined after 24 h and 48 h by measuring 5- bromo-2’-desoxyuridine (BrdU) incorporation. Additionally, the cells were trypsinized and prepared for cell cycle determination using propidium iodide for DNA staining. The stained cells were analyzed using a flow cytometer. Results: Folate inhibited cell proliferation moderately within 24 h. Its metabolites, dihydrofolate and 5-MTHF were more potent inhibitors of cell growth. Treatment with folate and 5-MTHF resulted in the accumulation of cells in G1-G0 phase of the cell cycle and decreased the number of cells in G2-M phase. In addition, cells treated with 5-MTHF were predominantly accumulated in the S-phase. There was no difference in cell cycle progression of Caco-2 cells treated with homocysteine in comparison to controls. In homocysteine-treated cells, both folate and 5-MTHF reversed the homocysteine-induced enhancement of growth. In contrast, folate reduced the Caco-2 cell growth rate to control values and 5-MTHF depleted growth of homocysteine-treated cells to levels significantly lower than controls. Conclusions: Our data suggest that 5-MTHF, being the key metabolite in both the folate and homocysteine metabolic pathway, is the main modulator of growth-promoting actions of homocysteine as well as antiproliferative effects of folate in colon cancer cells.


  • Cost‐effective and safe ambulatory long‐term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation

    by Dominik Faust, Holger F Rabenau, Regina Allwinn, Wolfgang F Caspary, Stefan Zeuzem

    Abstract: Background: Hepatitis B (HBV)‐infected patients receive an anti‐HBs immunoprophylaxis [hepatitis B immunoglobulin (HBIG) titre of more than 100 IU/L] in combination with lamivudine to prevent reinfection after orthotopic liver transplantation (OLT). In comparison with intramuscular (i.m.) HBIG, costs for intravenous (i.v.) HBIG are found to be extremely high. We therefore studied patients' outcome (i) after a switch from i.v. to i.m. HBIG and (ii) the outcome after the patients were initially treated with i.m. HBIG after discharge from the hospital.Methods: (i) Six outpatients were switched from 2000 IU i.v. HBIG (Hepatect®) administered every 2 wk to 2000 IU i.m. HBIG (Hepatitis‐B‐Immunglobulin Behring®) given once a month. (ii) Six other outpatients were directly treated with i.m. HBIG every 4 wk after OLT. All patients also received 100 mg lamivudine/d.Results: Patients switched from i.v. to i.m. HBIG had stable anti‐HBs titres (i.v. HBIG: 180 ± 37 IU/L vs. i.m. HBIG: 173 ± 23 IU/L). Patients directly treated with i.m. HBIG also had sufficient anti‐HBs titres (176 ± 31 IU/L). Intramuscular application of HBIG was well tolerated by all patients and no side‐effects were observed in patients receiving i.m. HBIG. In comparison with the protocol using i.v. HBIG, the costs of i.m. treatment were 60% lower.Conclusion: Long‐term administration of i.m. HBIG saves up to 60% of the usual costs for i.v. prophylaxis of HBV reinfection in patients after OLT. In combination with lamivudine, long‐term i.m. HBIG therapy is as efficient as i.v. HBIG treatment, but its lower costs clearly favour its use in preventing HBV reinfection after OLT.


  • Human peritoneal macrophages in culture: a model for studying inflammatory disorders in vitro

    by D. Faust, B. Akoglu, A.C. Faust, V. Milovic

    In this study we characterized a model of human peritoneal macrophages maintained in culture for up to 48 h that can be used to study different functions of this cell population in vitro. The cells remained viable and functionally active over time, with well-preserved phagocytic properties. They expressed a macrophage marker, CD14. Once in culture, human peritoneal macrophages secreted C1q and nitric oxide in a pattern described in murine, guinea pig, and rat peritoneal macrophages . The described model can be used to study physiology and pathophysiology of peritoneal macrophages in vitro, offering all the advantages of the use of a human cell population.


  • Anti-inflammatory drugs modulate C1q secretion in human peritoneal macrophages in vitro

    by Dominik Faust, Bora Akoglu, Dimitrios Zgouras, Ernst-Heinrich Scheuermann, Vladan Milovic, Jürgen Stein


  • Regulation ofα1-proteinase inhibitor release by proinflammatory cytokines in human intestinal epithelial cells

    by D. Faust, K. Raschke, S. Hormann, V. Milovic, J. Stein

    α1-Proteinase inhibitor (α1-PI) is the main serine proteinase inhibitor in human plasma. Apart from its synthesis in the liver, this anti-inflammatory protein is also synthesized by and excreted from human intestinal epithelial cells. Antiinflammatory actions of α1-PI are thought to be of relevance in the pathogenesis of inflammatory bowel disease. To investigate the role of macrophage-derived cytokines on α1-PI secretion from intestinal epithelial cells, we cultured Caco-2 cells until differentiation (14 days in culture) on permeable filter supports. Monolayers of differentiated Caco-2 cells were then co-cultured with human peritoneal macrophages, grown on plastic in the basolateral chamber. Under these conditions, α1-PI secretion from Caco-2 cells was enhanced by 45%, probably by a direct action of macrophage-derived cytokines on Caco-2 cells. To extend this observation further, we treated differentiated Caco-2 cells with macrophage-derived proinflammatory cytokines (IL-1β, IL-8, TNF-α), as well as with lymphocyte-derived cytokines IL-2, IL-6 and IFN-γ. As early as after 24h treatment, IL-2 and IL-8 induced a significant and dose-dependent increase of α-1-PI secretion into cell culture medium; this effect was completely reversed after immunoneutralization by the antibodies against IL-2 and IL-8 α1-PI secretion was only slightly decreased after treatment with IFN-γ, while IL-1β, IL-6 and TNF-α had no effect. α1-PI secretion correlated well with the expression of this protein in differentiated Caco-2 cells after cytokine treatment, as confirmed by Western blot. Our data imply that, in vitro, α1-PI secretion in enterocyte-like Caco-2 cells is up-regulated by IL-2 and IL-8. Our results suggest that both lymphocyte- and macrophage-derived cytokines regulate secretion of the anti-inflammatory protein α1-PI in intestinal epithelial cells.


  • Butyrate and the cytokine‐induced α1‐proteinase inhibitor release in intestinal epithelial cells

    by D. Faust, S. Hormann, M. Friedrich‐Sander, V. Milovic, J. Stein

    Alpha1-proteinase inhibitor (alpha1-PI), an anti-inflammatory protein thought to play a role in the intestinal inflammation, is synthesised by and released from the intestinal epithelial cells. IL-1beta is a key proinflammatory cytokine in the abnormal immune response that occurs in inflammatory bowel disease. Butyrate is a normal luminal constituent in the colon, known to be of benefit in preventing inflammatory bowel disease. Direct modes of action of butyrate in intestinal inflammation have been poorly studied so far. The aim of this study was to investigate the effects of butyrate on cytokine-mediated alpha1-PI release in intestinal epithelial cells. Differentiated Caco-2 cells were incubated with IL-1beta in the presence or absence of 2 mM butyrate. Alpha1-PI expression in the cells was evaluated by Western blot analysis and alpha1-PI release by ELISA. Treatment with butyrate alone had no effect on alpha1-PI expression in differentiated Caco-2 cells. However, treatment of the cells with 2 mM butyrate significantly reduced the alpha1-PI level in IL-1beta-treated cells. In the cell culture medium, the presence of butyrate impaired the IL-1beta-induced alpha1-PI release to 17-35%. The treatment induced no change in the number of detached cells or the percentage of viable cells. Our data show that butyrate inhibits alpha1-PI release from Caco-2 colonocytes treated with IL-1beta. It is therefore likely that anti-inflammatory actions of butyrate occur via a mechanism that does not involve direct regulation of cytokine-induced anti-inflammatory protein expression in intestinal epithelial cells.